AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11153617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 60
Study 9357882 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 302
Study 9357882 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice (SP group)
Number of subjects: 302
Study 8297924 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 39
Study 8297924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8297924 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 39
Study 8297924 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders (Amitriptyline, Placebo, Moclobemide)
Number of subjects: 39
Study 8297924 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 39
Study 3552839 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK YES)
Number of subjects: 209
Study 3552839 — intervention group
Group type: COMPARATOR
Intervention: No Streptokinase (SK NO)
Number of subjects: 209
Study 30071843 — intervention group
Group type: EXPERIMENTAL
Intervention: How-to Parenting Program (7-week group intervention)
Number of subjects: 0
Study 30071843 — intervention group
Group type: EXPERIMENTAL
Intervention: How-to Parenting Program
Number of subjects: 0
Study 30071843 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention during the trial)
Number of subjects: 0
Study 27276028 — intervention group
Group type: EXPERIMENTAL
Intervention: Water, sanitation, and hygiene intervention (adherence to two or three components)
Number of subjects: 185
Study 27276028 — intervention group
Group type: EXPERIMENTAL
Intervention: Water, sanitation, and hygiene intervention (adherence)
Number of subjects: 185
Study 27276028 — intervention group
Group type: COMPARATOR
Intervention: Control arm (zero or one intervention component)
Number of subjects: 185
Study 25393622 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0
Study 25393622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/MMF/steroids
Number of subjects: 0
Study 25393622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/MMF/steroids + Rituximab
Number of subjects: 0
Study 23732255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesita Azul ultraviolet-disinfection system
Number of subjects: 444
Study 20432107 — intervention group
Group type: EXPERIMENTAL
Intervention: National Youth Anti‐Drug Media Campaign (NYADMC) awareness
Number of subjects: 0
Study 18953854 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (oral or intravenous) administered from 2 hours before surgery to 30 days after surgery, dosage adjusted according to blood pressure and heart rate.
Number of subjects: 102
Study 18953854 — intervention group
Group type: COMPARATOR
Intervention: Control group (blank control group) receiving no metoprolol.
Number of subjects: 102
Study 17273608 — intervention group
Group type: COMPARATOR
Intervention: 200 microg of spray fenoterol (n = 41)
Number of subjects: 84
Study 17273608 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 microg of dry‐powder inhaler formoterol (n = 43)
Number of subjects: 84
Study 12966259 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% AMI
Number of subjects: 20
Study 12966259 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% KET
Number of subjects: 20
Study 12966259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination AMI 1%/KET 0.5%
Number of subjects: 20
Study 12966259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12966259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination cream (open-label phase)
Number of subjects: 20
Study 10100330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention course (behavior change skills taught in weekly lectures and peer-led labs)
Number of subjects: 338
Study 10100330 — intervention group
Group type: COMPARATOR
Intervention: Control course (knowledge-oriented)
Number of subjects: 338
Study 8875970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering interventions (low-fat/low-cholesterol diet, partial ileal bypass surgery, pharmacologic agents such as bile resins, fibrates, niacin, and HMG-CoA reductase inhibitors)
Number of subjects: 0
Study 8875970 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitors
Number of subjects: 0
Study 8875970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering interventions
Number of subjects: 0
Study 1725202 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg)
Number of subjects: 503
Study 1725202 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 503
Study 1725202 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg b.i.d.)
Number of subjects: 503
Study 1725202 — intervention group
Group type: COMPARATOR
Intervention: Diuretic (hydrochlorothiazide 50 mg and amiloride 5 mg)
Number of subjects: 503
Study 7200722 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate diet
Number of subjects: 57
Study 7200722 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein concentrate diet
Number of subjects: 57
Study 7200722 — intervention group
Group type: COMPARATOR
Intervention: Casein diet
Number of subjects: 57
Study 29693303 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal SOFA coagulation score (SOFA-CS ≥ 1)
Number of subjects: 1508
Study 29693303 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline of ≥60% in platelet counts
Number of subjects: 1508
Study 29693303 — intervention group
Group type: COMPARATOR
Intervention: Normal SOFA coagulation score (SOFA-CS = 0)
Number of subjects: 1508
Study 29600318 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal diathermy (ESMD)
Number of subjects: 29
Study 29600318 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal resection (ESMR)
Number of subjects: 29
Study 26293682 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA scans (spine, hip, whole body and forearm)
Number of subjects: 125
Study 26293682 — intervention group
Group type: EXPERIMENTAL
Intervention: HR‐pQCT scans (distal radius and tibia)
Number of subjects: 125
Study 26293682 — intervention group
Group type: EXPERIMENTAL
Intervention: QCT scans (spine and hip)
Number of subjects: 125
Study 26293682 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS
Number of subjects: 125
Study 24643055 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin for 4 weeks
Number of subjects: 80
Study 24643055 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate for 4 weeks
Number of subjects: 80
Study 21138499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium plus formoterol
Number of subjects: 1868
Study 21138499 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium alone
Number of subjects: 1868
Study 18047771 — intervention group
Group type: EXPERIMENTAL
Intervention: Active auditory verbal hallucinations (AVHs)
Number of subjects: 46
Study 18047771 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of speaking voice as non-self
Number of subjects: 46
Study 18047771 — intervention group
Group type: EXPERIMENTAL
Intervention: Loudness and clarity of sound images
Number of subjects: 46
Study 16150550 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout group
Number of subjects: 74
Study 16150550 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 74
Study 14510041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-structure, behaviorally oriented (HSB) treatment
Number of subjects: 120
Study 14510041 — intervention group
Group type: COMPARATOR
Intervention: Low-structure, facilitative (LSF) treatment
Number of subjects: 120
Study 11098028 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management (group A)
Number of subjects: 50
Study 11098028 — intervention group
Group type: COMPARATOR
Intervention: Oral contraception (group B)
Number of subjects: 50
Study 11098028 — intervention group
Group type: COMPARATOR
Intervention: No treatment after second cycle
Number of subjects: 50
Study 8884859 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (group A, n = 46) - 2 x 10(5) KIU before incision, 2 x 10(6) KIU in priming solution, 5 x 10(5) KIU/h during CPB
Number of subjects: 93
Study 8884859 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group B, n = 47)
Number of subjects: 93
Study 1411667 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg controlled-release salbutamol (CRS)
Number of subjects: 10
Study 1411667 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg controlled-release salbutamol (CRS)
Number of subjects: 10
Study 1411667 — intervention group
Group type: COMPARATOR
Intervention: Placebo CRS
Number of subjects: 10
Study 2865721 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol for induction and maintenance of anaesthesia, 9.0 mg/kg/h for 30 min followed by 4.5 mg/kg/h supplemented with fentanyl
Number of subjects: 0
Study 2865721 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 0
Study 31524046 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 40
Study 31524046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 40
Study 30383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitated elicitation on the ISS
Number of subjects: 267
Study 30383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitated elicitation on the ISS (M = 2:18 min, SD = 0:59 min)
Number of subjects: 267
Study 30383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitated productions
Number of subjects: 267
Study 30383182 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous productions
Number of subjects: 267
Study 30383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Word-initial position
Number of subjects: 267
Study 30383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of consonants correct across word positions
Number of subjects: 267
Study 28452866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine reuptake inhibitor (methylphenidate)
Number of subjects: 12
Study 28452866 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine reuptake inhibitor (reboxetine)
Number of subjects: 12
Study 28452866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26423001 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Support Psychotherapy (GSP)
Number of subjects: 109
Study 26423001 — intervention group
Group type: COMPARATOR
Intervention: Group HIV Education (GHE)
Number of subjects: 109
Study 23907995 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg eteplirsen
Number of subjects: 12
Study 23907995 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg eteplirsen
Number of subjects: 12
Study 23907995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20885302 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic feedback from standardized assessment tools
Number of subjects: 709
Study 20885302 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (Control)
Number of subjects: 709
Study 19219630 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 173
Study 19219630 — intervention group
Group type: COMPARATOR
Intervention: Control (no further local treatment)
Number of subjects: 173
Study 16325429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency acupoint stimulation (HF: 100 Hz)
Number of subjects: 12
Study 16325429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency acupoint stimulation (LF: 2 Hz)
Number of subjects: 12
Study 16325429 — intervention group
Group type: COMPARATOR
Intervention: Mock point stimulation
Number of subjects: 12
Study 14628428 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU/Lev (50 mg orally three times/day for 3 days, repeated every 2 weeks for 1 year)
Number of subjects: 185
Study 14628428 — intervention group
Group type: COMPARATOR
Intervention: 5FU alone (450 mg/m2 i.v. bolus daily for 5 days and then weekly for 48 weeks)
Number of subjects: 185
Study 14628428 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU/Lev and 5FU alone
Number of subjects: 185
Study 11104315 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment for anxious ADHD children
Number of subjects: 100
Study 11104315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 100
Study 11104315 — intervention group
Group type: COMPARATOR
Intervention: Medication response
Number of subjects: 100
Study 9347433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 81
Study 9347433 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 81
Study 8247036 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of cisplatin (100 mg/m²) and cyclophosphamide (300 mg/m²)
Number of subjects: 105
Study 8247036 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of cisplatin (80 mg/m²) and cyclophosphamide (225 mg/m²)
Number of subjects: 105
Study 8247036 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of cisplatin and cyclophosphamide
Number of subjects: 105
Study 8247036 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of cisplatin and cyclophosphamide
Number of subjects: 105
Study 3440987 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction programme supervised by dietitians
Number of subjects: 0
Study 3440987 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-dieting obese hypertensive patients)
Number of subjects: 0
Study 3440987 — intervention group
Group type: COMPARATOR
Intervention: Weight reduction programme for obese normotensive patients
Number of subjects: 0
Study 30420969 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 68
Study 30420969 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus Oral Hypoglycemic Agents (OHAs)
Number of subjects: 68
Study 30420969 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine plus OHAs
Number of subjects: 68
Study 29944308 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 154
Study 29944308 — intervention group
Group type: COMPARATOR
Intervention: Daily Proguanil
Number of subjects: 154
Study 23872937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball skill intervention (practiced in relative static, simple settings and more dynamic and cognitive demanding settings)
Number of subjects: 91
Study 23872937 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the school's regular physical education lessons)
Number of subjects: 91
Study 23872937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball skill intervention
Number of subjects: 91
Study 23872937 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 22763796 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate SWL
Number of subjects: 0
Study 22763796 — intervention group
Group type: COMPARATOR
Intervention: Delayed SWL
Number of subjects: 0
Study 20097076 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight support at 0%, 20%, 40%, 60%, 100% with stride frequency at 0.40, 0.49, 0.57 Hz
Number of subjects: 8
Study 20097076 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of body weight support and faster stride frequencies
Number of subjects: 8
Study 20097076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of body weight support and slower stride frequency
Number of subjects: 8
Study 18539666 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone acetonide, bupivacaine, and epinephrine
Number of subjects: 90
Study 18539666 — intervention group
Group type: COMPARATOR
Intervention: Injection mixture without triamcinolone (Control)
Number of subjects: 90
Study 16921006 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered training with showering for 6 weeks (Time 1)
Number of subjects: 69
Study 16921006 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered training with towel bath for 6 weeks (Time 2)
Number of subjects: 69
Study 16921006 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered training (both interventions)
Number of subjects: 69
Study 16921006 — intervention group
Group type: COMPARATOR
Intervention: Usual showering procedures without person-centered training
Number of subjects: 69
Study 12676261 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine 500 mg i.v. prior to each radiotherapy fraction
Number of subjects: 54
Study 12676261 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 54
Study 11077135 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (6 g/24 h for 3 days)
Number of subjects: 25
Study 11077135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11077135 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 25
Study 8915139 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 1% applied topically after UVB irradiation (300 and 320 nm)
Number of subjects: 0
Study 8915139 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 1% applied topically after UVA2 irradiation (330 and 340 nm)
Number of subjects: 0
Study 8915139 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 1% applied topically after UVA1 irradiation (350 and 370 nm)
Number of subjects: 0
Study 1348663 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 275 mg (two capsules)
Number of subjects: 44
Study 1348663 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two identical capsules)
Number of subjects: 44
Study 6140355 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic women who later acquired other endocrine disease
Number of subjects: 95
Study 6140355 — intervention group
Group type: COMPARATOR
Intervention: Insulin-dependent diabetic women without other endocrine disease
Number of subjects: 95
Study 6140355 — intervention group
Group type: EXPERIMENTAL
Intervention: First pregnancy of women with other endocrine disease
Number of subjects: 95
Study 6140355 — intervention group
Group type: EXPERIMENTAL
Intervention: Second pregnancy of women with other endocrine disease
Number of subjects: 95
Study 6140355 — intervention group
Group type: EXPERIMENTAL
Intervention: Third pregnancy of women with other endocrine disease
Number of subjects: 95
Study 6140355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth pregnancy of women with other endocrine disease
Number of subjects: 95
Study 6140355 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of women with other endocrine disease
Number of subjects: 95
Study 6140355 — intervention group
Group type: COMPARATOR
Intervention: Offspring of other diabetic mothers
Number of subjects: 95
Study 31356450 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) plus treatment-as-usual (TAU)
Number of subjects: 225
Study 31356450 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 225
Study 31356450 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroQoL plus TAU
Number of subjects: 225
Study 31356450 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 225
Study 29373393 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-Release Naltrexone (XR-NTX)
Number of subjects: 93
Study 29373393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 27312514 — intervention group
Group type: EXPERIMENTAL
Intervention: pemetrexed-cisplatin
Number of subjects: 97
Study 27312514 — intervention group
Group type: COMPARATOR
Intervention: etoposide-cisplatin
Number of subjects: 97
Study 25417609 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard enteral product added to regulated hospital diets
Number of subjects: 38
Study 25417609 — intervention group
Group type: COMPARATOR
Intervention: Regulated hospital diets only
Number of subjects: 38
Study 25417609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Study and Control)
Number of subjects: 38
Study 22529301 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC‐HIV (vCP1521) and AIDSVAX B/E vaccine
Number of subjects: 71
Study 22529301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 20598985 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 589
Study 20598985 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 589
Study 20598985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Valsartan and Captopril
Number of subjects: 589
Study 20598985 — intervention group
Group type: COMPARATOR
Intervention: Control group (other causes of death)
Number of subjects: 589
Study 18222373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7.5%) resuscitation with or without dextran
Number of subjects: 5848
Study 18222373 — intervention group
Group type: COMPARATOR
Intervention: Conventional isotonic resuscitation
Number of subjects: 5848
Study 16001651 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 103
Study 16001651 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 12427399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal estradiol 300 microg/day (one spray delivery of 150 microg per nostril)
Number of subjects: 201
Study 12427399 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol 2 mg/day
Number of subjects: 201
Study 10518632 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Bioequivalence (IBE)
Number of subjects: 0
Study 10518632 — intervention group
Group type: EXPERIMENTAL
Intervention: Population Bioequivalence (PBE)
Number of subjects: 0
Study 10518632 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling methodology
Number of subjects: 0
Study 10518632 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadening BE limits
Number of subjects: 0
Study 7723351 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil 50 mg
Number of subjects: 10
Study 7723351 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil 100 mg
Number of subjects: 10
Study 7723351 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil 200 mg
Number of subjects: 10